Table 1 Baseline clinical features of 133 patients with RR-cHL treated with Nivolumab

No.

133

Age (years)

 Median, (range), years

35 (15–82)

Gender

 Male

84 (63.2)

 Female

49 (36.8)

ECOG PS

 0–1

109 (81.9)

 ≥ 2

24 (18.1)

Histology

 Nodular sclerosing

106 (79.7)

 Mixed cellularity

8 (6)

 Lymphocyte rich

2 (1.5)

 Lymphocyte depleted

2 (1.5)

 Hodgkin lymphoma unspecified

15 (11.3)

B-symptoms

83/131 (63.3)

Bulky disease

31/131 (23.6)

Stage III–IV

98/130 (75.4)

Bone marrow involvement

12/109 (11)

Previous treatment lines

 Median (range)

4 (1–9)

 1–2

8 (6)

 3–4

68 (51.1)

 ≥ 5

57 (42.9)

Previous stem cell transplantation

 Autologous^a

76 (57.1)

 Allogeneic

28 (21)

Prior Brentuximab Vedotin

128 (96.2)

Nivolumab doses received

 Median (range)

18 (1–57)

BMI (kg/m²)

 Median (range)

24.1 (16.5–44.4)

 Underweight (BMI ≤ 18.5)

12 (9)

 Normal weight (BMI 18.5 < BMI ≤ 24.9)

66 (49.6)

 Overweight (25 < BMI ≤ 29.9)

31 (23.3)

 Obese (BMI ≥ 30)

24 (18.1)